Burlington, Massachusetts, April 12, 2018 — MilliporeSigma today announced a partnership with Oxford University’s Jenner Institute to develop more robust and scalable vaccine manufacturing processes. This partnership, as well as plans to develop a vaccine manufacturing facility in Ghana, further the company’s commitment to improving global health by making vaccines more affordable and available.
“The collaboration with the Jenner Institute will facilitate access to affordable vaccines while improving the global response to disease outbreaks,” said Udit Batra, CEO of MilliporeSigma. “MilliporeSigma is committed to expanding access to advanced drug therapies, especially in low- and middle-income countries. Together, with our partners, we have shaped how vaccine production is done today and are helping to solve the toughest problems of tomorrow.”
Through the collaboration with the Jenner Institute, the partners will improve the manufacturing process for adenovirus vaccines — vaccines based on adenovirus, a type of DNA virus, as a carrier — using MilliporeSigma products, systems and technologies on a real-world feed stream. By applying MilliporeSigma technology, the collaborators aim to develop a cost-effective and transferable manufacturing process that can be used to accelerate vaccine development and manufacturing worldwide.
“MilliporeSigma is an excellent partner for enhancing our capabilities in adenovirus vaccine development, as the newly developed process should match or exceed our existing process in terms of productivity and purity,” said Adrian Hill, Director of the Jenner Institute at Oxford University.
The collaboration should result in a closed process that can be practiced in a cleanroom to minimize contamination, in line with the high biological safety requirements for viral vectors.
“Such improvements should help advance the development of clinical-grade, injectable drug product for use in clinical trials and other research applications,” Hill added.
MilliporeSigma building vaccine facility in Ghana
Separately, MilliporeSigma is developing plans for a vaccine manufacturing facility in Ghana, helping to address significant health challenges in a continent that imports 99 percent of its vaccines. Working with Ridge Management Solutions, a recently signed memorandum of understanding between MilliporeSigma and Ridge provides the opportunity for Ghana to become the first country in Sub-Saharan Africa to have a dedicated human vaccine manufacturing factory.
“We want to support emerging economies by sharing our expertise, helping them streamline their manufacturing processes while supporting technology transfer and local facility startup,” Batra added.
For more information on how MilliporeSigma collaborates with the vaccine community to solve the toughest challenges in vaccine production, visit www.emdmillipore.com/vaccines.
About the Jenner Institute
The Jenner Institute was founded in November 2005 to develop innovative vaccines against major global diseases. Uniquely it focuses both on diseases of humans and livestock and tests new vaccine approaches in parallel in different species. A major theme is translational research involving the rapid early-stage development and assessment of new vaccines in clinical trials.
The Institute comprises the research activities of over 30 Jenner Investigators who head leading research groups spanning human and veterinary vaccine research and development. Together the Institute Investigators comprise one of the largest non-profit sector research and development activities in vaccinology.
Jenner Institute Investigators, through the support of many funders, are developing new vaccine candidates against major global infectious diseases. New vaccines against malaria, tuberculosis and HIV are currently in field trials in the developing world. Research is also underway on livestock vaccines against foot and mouth disease, avian influenza, bovine tuberculosis and other major causes of economic loss.
The Institute is a partnership between the University of Oxford and the The Pirbright Institute and is the successor to the former Edward Jenner Institute for Vaccine Research. The Institute is supported by the Jenner Vaccine Foundation, a UK registered charity and advised by the Jenner Institute Scientific Advisory Board.
About Ridge Management Solutions
There’s a 5 percent chance that a hurricane will cause $60 billion of insured losses next year and a 1% chance an earthquake will cause $50 billion of insured loss in the next 12 months. At RMS, we build the simulation models that allow insurers and investors to understand portfolio risks due to catastrophes: natural catastrophes (hurricane, earthquake, flood), terrorism, pandemic, and changes in life expectancy. We are one of the most exciting companies you’ve probably “never” heard of, unless you’re one of our hundreds of clients in the (re)insurance, banking or hedge fund sector. We lead an industry we helped pioneer and ultimately our work makes a true impact on the world at large. How we understand and manage risk affects everybody and our passion is nothing less than creating a more resilient world through a better understanding of catastrophic events.
We are evolving our vision by delivering future solutions in the cloud, our cutting-edge risk management platform “RMS(one)” for the global risk market. RMS(one) will create a holistic and integrated view across the enterprise with one platform for all models, all points of view, and all data. All will be run as equal partners on RMS(one).
RMS has 1,200 employees in 11 countries, including offices in Newark (CA-USA), Noida (India), London (UK), Hoboken (NJ-USA), and Zurich (Switzerland).
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.